Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research into strokes and vascular dementia has taken a major step forward following the official opening of the Wolfson Centre for the Prevention of Stroke and Dementia (CPSD) in Oxford, based at the new Wolfson Building at the John Radcliffe Hospital.

New Wolfson Building

The new centre is the only purpose-built clinical research centre looking specifically at stroke and dementia in the UK, and will house an estimated 25% of all the UK’s active stroke researchers. Funding for the CPSD, and the new Wolfson Building, was provided by the Wolfson Foundation and the Wellcome Trust.

The CPSD, part of the University of Oxford’s Nuffield Department of Clinical Neurosciences (NDCN), was officially opened by Emeritus Professor of Medical Neurology, Charles Warlow, the neurologist who first developed stroke research in the UK.

The ceremony was followed by a celebration reception for the new Wolfson Building, which also houses an annexe for the Wellcome Centre for Integrative Neuroimaging (WIN), also a part of the NDCN.

The CPSD is funded by the Wolfson Foundation, the Wellcome Trust and the University of Oxford. Many of the researchers based at the centre are funded by the NIHR Oxford Biomedical Research Centre.

The CPSD will allow substantial expansion of the previous Stroke Prevention Research Unit, already regarded as one of the most productive stroke research groups in the world.

The researchers use a broad range of techniques to increase our understanding of the causes of cerebrovascular disease and improve the prevention of stroke in routine clinical practice. These include large population-based cohort studies, state-of-the-art brain and blood vessel imaging and biobanks.

Gavin Screaton, Head of the University of Oxford’s Medical Sciences Division, said: “There are 1.2 million stroke survivors in the UK, and someone has a stroke here every five minutes. This new state-of-the-art centre represents a major step forward for stroke and vascular dementia research, not only in Oxford, but in the UK.

“Given the relatively large number of scientists and clinicians working here, the new expanded centre promises to keep Oxford at the forefront of research in this field, and ensure that we continue to deliver benefits for patients.”

Dr Bruno Holthof, Chief Executive Officer of Oxford University Hospitals NHS Foundation Trust, said “We are very privileged to see another leading medical research facility – and the UK’s first dedicated centre for stroke and dementia research – opening on the John Radcliffe site.  This new centre brings together clinicians and researchers from the Trust and the University to improve diagnosis and treatment for patients.  

Our clinical work has been informed by research from the Centre for the Prevention of Stroke and Dementia, and equally we aim to offer all our stroke patients the opportunity to take part in a research study, as this could be crucial for preventing strokes or improving treatment in future.”

The work of the CPSD has already led to major changes in clinical practice and guidelines, such as demonstrating the benefits of emergency treatment after a mini-stroke or TIA to prevent major stroke.

“Cerebrovascular disease is the leading cause of neurological disability in the UK and the most costly in terms of health and social care. Stroke and dementia share risk factors and often co-exist, each increasing the risk and severity of the other,” Professor Peter Rothwell, Founding Director of the CPSD, said.

“Stroke is as common as cancer or heart disease, but has received much less research funding in the past. More needs to be done to invest in stroke research, and the establishment of this centre is a positive step forward in this regard.

“Equally, vascular dementia makes up around 25 percent of all dementia in the UK, yet it receives much less funding than other kinds of dementia, such as Alzheimer’s. This centre – the only one of its kind in the country researching vascular dementia – also has an important role to play in tackling this condition,” Prof Rothwell said.

“The opening of this new centre is an opportunity to thank the patients who take part in our research. Almost 15,000 people have taken part in our Oxford Vascular Study looking at how common vascular disease is and how it affects people’s lives. Around 95 percent of patients we approach agree to take part in our research, for which we are enormously grateful.”

The Wolfson Building, which was designed by Oxford-based architects fjmt and built by contractor SDC, will also be home to researchers from the Wellcome Centre for Integrative Neuroimaging (WIN), who are investigating how the brain recovers after damage and how the brain processes pain.

Similar stories

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

Daniel Freeman to join Department of Experimental Psychology as Professor of Psychology

The Department of Experimental Psychology are delighted to announce that Daniel Freeman has been appointed as their new Professor of Psychology, joining from the Department of Psychiatry.

New study reveals role of lymphatic system in bone healing

It was previously assumed that bones lacked lymphatic vessels, but new research from the MRC Human Immunology Unit at Oxford's MRC Weatherall Institute for Molecular Medicine not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.

Vaccination shown to protect against pregnancy complications from COVID-19 Omicron variant

The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has today published, in The Lancet, the results of the ‘2022 INTERCOVID Study’ conducted in 41 hospitals across 18 countries.